Lipocalin 2 as a clinical significance in rheumatoid arthritis

Basit Öğe Kaydı
dc.authoridPOYRAZ, AHMET KURSAD/0000-0001-8992-1743
dc.authorwosidGulkesen, Arif/V-9759-2018
dc.authorwosidKaya, Arzu/W-7138-2018
dc.authorwosidYildirim, Tulay/AAB-5030-2021
dc.authorwosidPOYRAZ, AHMET KURSAD/B-7716-2009
dc.contributor.authorGulkesen, Arif
dc.contributor.authorAkgol, Gurkan
dc.contributor.authorPoyraz, Ahmet K.
dc.contributor.authorAydin, Suleyman
dc.contributor.authorDenk, Affan
dc.contributor.authorYildirim, Tulay
dc.contributor.authorKaya, Arzu
dc.date.accessioned2024-08-04T20:44:06Z
dc.date.available2024-08-04T20:44:06Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAim of the study: In this study, serum lipokalin 2 (LCN-2) levels and its clinical and radiological significance in patients with rheumatoid arthritis was evaluated. Material and methods: The study enrolled 37 patients with RA and 34 healthy controls. Serum LCN-2 level was measured using ELISA method. Patients with DAS 28 scores <= 3.2, and > 3.2 were allocated into lower and high/moderate disease activity groups, respectively. Additionally patients were divided into 2 groups as early RA (disease duration <= 2 years) and established RA (duration of the disease >= 2 years). Functional disability was evaluated using Health Assessment Questionnaire (HAQ). Radiographs were scored using the modified Larsen score. Results: Serum LCN-2 (p = 0.029) levels were significantly higher in patients with RA than in the controls. Serum LCN-2 level did not correlate with laboratory and clinical parameters of disease activity like erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), DAS 28, Health Assessment Questionnaire Score (HAQ) and Nottingham Health Profile (NHP). Similarly, any correlation could not be found between structural joint damage and serum LCN2 levels. Conclusions: These results indicate that serum LCN-2 levels may be used as an indicator for structural damage like erosions in the early stage of the disease but do not able to be used to monitor disease activity.en_US
dc.identifier.doi10.5114/ceji.2017.70969
dc.identifier.endpage273en_US
dc.identifier.issn1426-3912
dc.identifier.issn1644-4124
dc.identifier.issue3en_US
dc.identifier.pmid29204091en_US
dc.identifier.scopus2-s2.0-85032822018en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage269en_US
dc.identifier.urihttps://doi.org/10.5114/ceji.2017.70969
dc.identifier.urihttps://hdl.handle.net/11616/98016
dc.identifier.volume42en_US
dc.identifier.wosWOS:000415131100007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTermedia Publishing House Ltden_US
dc.relation.ispartofCentral European Journal of Immunologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectrheumatoid arthritisen_US
dc.subjectdisease activityen_US
dc.subjectlipokalin 2en_US
dc.subjectmodified Larsen scoreen_US
dc.titleLipocalin 2 as a clinical significance in rheumatoid arthritisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu